Hologic, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Malenchini
- Full Time Employees
- 7,063
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 250 Campus Drive Marlborough MA United States of America 01752
- IPO Date
- Mar 1, 1990
- CIK
- 0000859737
- Website
- hologic.com
- Similar Companies
- Business
- Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products focused on women's health. The company operates through four primary segments: Diagnostics, offering molecular diagnostic assays such as Aptima for women's health screening including HPV and STI testing, as well as blood screening solutions; Breast Health, providing digital mammography systems like Selenia Dimensions 3D, Genius AI detection technology, breast biopsy systems, and pathology solutions; GYN Surgical, featuring devices including the MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu radiofrequency ablation system, CoolSeal vessel sealing portfolio, and JustRight surgical stapler; and Skeletal Health, encompassing the Horizon DXA bone densitometry and Fluoroscan Insight FD mini C-arm systems. Founded in 1985 and headquartered in Marlborough, Massachusetts, Hologic serves healthcare providers and laboratories worldwide, with major revenue from the United States, Europe, and Asia. In October 2025, the company agreed to be acquired by private equity firms Blackstone and TPG for up to $79 per share in an $18.3 billion deal including debt, expected to close in the first half of 2026 pending approvals, marking a shift to private ownership to accelerate innovation and growth; recent developments also include expanding the Panther molecular diagnostics platform with Fusion add-on for enhanced PCR and TMA capabilities, development of new gastrointestinal and healthcare-associated infection assays, organizational enhancements in breast health sales execution, and the anticipated launch of the Envision mammography platform in 2026.
OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay
New Evidence Backs Hologic's AI-Powered Mammography Technology for Detecting Challenging Cancers
Blackstone and TPG Complete Acquisition of Hologic
Hologic Target of Unusually Large Options Trading (NASDAQ:HOLX)
Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600
Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Go-Private Transaction
Exchange Traded Concepts LLC Lowers Position in Hologic, Inc. $HOLX
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Hologic (NASDAQ:HOLX) Hits New 52-Week High – Time to Buy?
HOLX vs. ALGN: Which MedTech Stock Is the Better Investment Pick Now?
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Hologic's Women's Health Index Flags Alarming Gaps in STI Screening
Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?
1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates
Cinctive Capital Management LP Buys 23,119 Shares of Hologic, Inc. $HOLX
Arrowpoint Investment Partners Singapore Pte. Ltd. Takes $576,000 Position in Hologic, Inc. $HOLX
What Drives Hologic's GYN Surgical Strength in a Competitive Market?
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?
Becker Capital Management Inc. Boosts Holdings in Hologic, Inc. $HOLX